According to the World Health Organization (WHO) forecasts, in 2030, the number of people suffering from dementia will reach 82 million people worldwide, representing a huge burden on health and social care systems. Epidemiological data indicates a relationship between coronary heart disease (CHD) and the occurrence of cognitive impairment (CI) and dementia. It is known that both diseases have common risk factors. However, the impact of myocardial infarction (MI) on cognitive function remains controversial and largely unknown. The main goal of this study is to attempt to summarize and discuss selected scientific reports on the causes, mechanisms and effects of CI in patients after acute coronary syndrome (ACS), especially after MI. The risk of CI can increase in patients after ACS, and can therefore also adversely affect the further course of treatment. A late diagnosis of CI can lead to serious clinical implications, such as an increase in the number of hospitalizations and mortality.
(1) Background: Assessment of cognitive function is not routine in cardiac patients, and knowledge on the subject remains limited. The aim of this study was to assess post-myocardial infarction (MI) cognitive functioning in order to determine the frequency of cognitive impairment (CI) and to identify factors that may influence it. (2) Methods: A prospective study included 468 patients hospitalized for MI. Participants were assessed twice: during the first hospitalization and 6 months later. The Mini-Mental State Examination was used to assess the occurrence of CI. (3) Results: Cognitive dysfunction based on the MMSE was found in 37% (N-174) of patients during the first hospitalization. After 6 months, the prevalence of deficits decreased significantly to 25% (N-91) (p < 0.001). Patients with CI significantly differed from those without peri-infarction deficits in the GFR, BNP, ejection fraction and SYNTAX score, while after 6 months, significant differences were observed in LDL and HCT levels. There was a high prevalence of non-cognitive mental disorders among post-MI patients. (4) Conclusions: There is a high prevalence of CI and other non-cognitive mental disorders, such as depression, sleep disorders and a tendency to aggression, among post-MI patients. The analysis of the collected material indicates a significant impact of worse cardiac function expressed as EF and BNP, greater severity of coronary atherosclerosis expressed by SYNTAX results, and red blood cell parameters and LDL levels on the occurrence of CI in the post-MI patient population.
21 September 2021 in DARU Journal of Pharmaceutical Sciences
Introduction: Sodium-glucose cotransporter (SGLT2) inhibitors may additionally benefit patients with diabetes by improving their erythropoiesis followed by the elevation of hemoglobin and hematocrit levels. Reason for the report: In the case described, severe normocytic normochromic anemia was resolved when empagliflozin had been introduced to the therapy. Case summary: A 78-year-old male patient was admitted to our hospital with a non-ST-segment elevation myocardial infarction. His past medical history included diabetes, right coronary artery angioplasty, myocardial infarction and paroxysmal atrial fibrillation which required anticoagulant treatment. When examined, severe normocytic normochromic anemia was also diagnosed. About two years prior to his admission, the patient began suffering from persistent anemia despite the modification of his anticoagulant therapy with warfarin, rivaroxaban and dabigatran. An extensive evaluation failed to provide an explanation for his anemia. Outcome: Eventually, only the introduction of empagliflozin successfully increased the values of hemoglobin and hematocrit. Therefore, it transpires that SGLT2 enhances erythropoietin (EPO) secretion which subsequently raises hematocrit levels in patients with severe anemia. Graphic
At present hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This update focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, Systemic Inflammatory Index (SII), Systemic Inflammatory Response Index (SIRI) and Lipoprotein (a). Novel inflammatory-lipid biomarkers such as hsCRP to high density lipoprotein cholesterol (HDL-C) ratio, Neutrophils to HDL-C ratio, and Monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be a promising clinical tool for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.
We analysed cognitive impairment (CI) during the peri-myocardial infarction (MI) period and after 6 months. The study included 326 patients. Cognitive function was assessed using the Mini–Mental State Examination (MMSE) and the Clock Drawing Test (CDT). Routine laboratory and echocardiography data were collected. We distinguished 4 groups of patients: 1 – CI present peri-infarction and after 6 months; 2 – CI present only peri-infarction; 3 – CI present only after 6 months; 4 – without CI. Groups constituted 8.9%, 16.3%, 7.7% and 67.1% of participants (as assessed by MMSE), respectively. In those who improved (group 2) or with worsened cognitive function (group 3), analogous changes in attention function occurred. There was a group of patients with CI on the MMSE who performed the CDT correctly, 12% peri-infarct and 11% at 6-month follow-up, respectively. Patients with a normal CDT score but CI found in the MMSE had impaired attention function. Cognitive function improves in some patients, and deteriorates in others after MI. The uniform type of impaired cognitive function allows us to assume a uniform etiology of CI. Performing the CDT and using the MMSE component assessing attention could prove sufficient for the initial assessment of cognitive functions in patients after MI.